STAT Virtual Event: The ESMO Recap, Live!
Editor’s note: A live stream of the event will be embedded above at 1:30 p.m….
Category: ESMO20
STAT Plus: Amgen’s KRAS-blocking cancer drug shows durable responses, with tempered expectations
Amgen said Sunday that patients with advanced lung cancer who were given its drug to…
STAT Plus: New drug combination extends survival with advanced kidney cancer. It’s poised to enter a competitive treatment market
Patients with advanced kidney cancer live longer when treated with a combination of drugs from…
STAT Plus: Promising results for previously secret cancer drug data that ‘justified’ Gilead Sciences’ $21 billion acquisition
When Gilead Sciences announced its $21 billion acquisition of Immunomedics one week ago, Gilead executives…